Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ABS-1230

Phase 2Small molecule

AActio Biosciences, Inc.

ABS-1230 is one of 48 small molecule programs targeting Epilepsy. It is currently in Phase 2.

1

Indications

2

Total Trials

2

Active Trials

47

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpilepsyRecruiting

EpilepsyPhase 2

Recruiting

Competition

Competitive Landscape

87 competitors in Epilepsy

#DrugCompanyPhaseTrials

Vimpat

Tegretol

Fycompa

CCatalyst Biosciences

Lexapro

Briviact

Dilantin

VViatris Specialty LLC

Zoloft

VViatris Specialty LLC

Epidiolex

Jazz Pharmaceuticals

Ketalar

AAultman Health Foundation

Kynmobi

SSamson Clinical Operations Pty Ltd

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Epilepsy

NCT07156201

Q1 2028

Phase 2Recruiting

Epilepsy

NCT07600736

Clinical

Trials by Indication[1]

Epilepsy2 trials

A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric and Young Adult Participants With KCNT1-Related Epilepsy

Recruiting·AActio Biosciences, Inc.·Phase 2·NCT07600736·61 enrolled

A First-in-Human, Phase 1a, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose and Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Administered Orally to Healthy Adults

Recruiting·AActio Biosciences, Inc.·Phase 1·NCT07156201·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ABS-1230. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABS-1230 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABS-1230. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Actio Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AActio Biosciences, Inc.

Related News